Sun Pharma Q3 net doubles to ₹1,852 cr; declares interim dividend of ₹5.50 per share

- Consolidated total revenue from operations increased 8% to ₹8,837 cr
- 'Our Q3 performance reflects continued profitable business growth in a market that is gradually recovering from the impact of the global pandemic,' says MD Dilip Shanghvi